Tobias Kiesslich

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/193054/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Chemoresistance and resistance to targeted therapies in biliary tract cancer: what have we learned?. Expert Opinion on Investigational Drugs, 2022, 31, 221-233.	1.9	5
2	Ferroptosis in Hepatocellular Carcinoma: Mechanisms, Drug Targets and Approaches to Clinical Translation. Cancers, 2022, 14, 1826.	1.7	23
3	Immunmodulatory Treatment Strategies of Hepatocellular Carcinoma: From Checkpoint Inhibitors Now to an Integrated Approach in the Future. Cancers, 2021, 13, 1558.	1.7	8
4	The challenges of combinatory immunotherapy for biliary tract cancer. Expert Opinion on Investigational Drugs, 2021, 30, 591-594.	1.9	1
5	Systematic Review on Optical Diagnosis of Early Gastrointestinal Neoplasia. Journal of Clinical Medicine, 2021, 10, 2794.	1.0	9
6	HDAC Screening Identifies the HDAC Class I Inhibitor Romidepsin as a Promising Epigenetic Drug for Biliary Tract Cancer. Cancers, 2021, 13, 3862.	1.7	17
7	MiR-200c-3p Modulates Cisplatin Resistance in Biliary Tract Cancer by ZEB1-Independent Mechanisms. Cancers, 2021, 13, 3996.	1.7	7
8	Citation inequality and the Journal Impact Factor: median, mean, (does it) matter?. Scientometrics, 2021, 126, 1249-1269.	1.6	15
9	A Preoperative Clinical Risk Score Including C-Reactive Protein Predicts Histological Tumor Characteristics and Patient Survival after Surgery for Sporadic Non-Functional Pancreatic Neuroendocrine Neoplasms: An International Multicenter Cohort Study. Cancers, 2020, 12, 1235.	1.7	12
10	How do we choose the appropriate chemotherapeutic agents for biliary tract cancer?. Expert Opinion on Pharmacotherapy, 2020, 21, 243-245.	0.9	0
11	Long Non-Coding RNAs in Biliary Tract Cancer—An Up-to-Date Review. Journal of Clinical Medicine, 2020, 9, 1200.	1.0	14
12	Generation of An Endogenous FGFR2–BICC1 Gene Fusion/58 Megabase Inversion Using Single-Plasmid CRISPR/Cas9 Editing in Biliary Cells. International Journal of Molecular Sciences, 2020, 21, 2460.	1.8	3
13	Low VDAC1 Expression Is Associated with an Aggressive Phenotype and Reduced Overall Patient Survival in Cholangiocellular Carcinoma. Cells, 2019, 8, 539.	1.8	6
14	HDAC inhibitors in liver cancer: which route to take?. Expert Review of Gastroenterology and Hepatology, 2019, 13, 515-517.	1.4	5
15	The Cancer Stem Cell Inhibitor Napabucasin (BBI608) Shows General Cytotoxicity in Biliary Tract Cancer Cells and Reduces Cancer Stem Cell Characteristics. Cancers, 2019, 11, 276.	1.7	22
16	Size matters! Association between journal size and longitudinal variability of the Journal Impact Factor. PLoS ONE, 2019, 14, e0225360.	1.1	5
17	NRF2: The key to tumor- and patient-dependent chemosensitivity in biliary tract cancer?. EBioMedicine, 2019, 49, 9-10.	2.7	4
18	Exploring the surgical landscape of pancreatic neuroendocrine neoplasia in Austria: Results from the ASSO pNEN study group. European Journal of Surgical Oncology, 2019, 45, 198-206.	0.5	12

TOBIAS KIESSLICH

#	Article	IF	CITATIONS
19	Continuous, label-free, 96-well-based determination of cell migration using confluence measurement. Cell Adhesion and Migration, 2019, 13, 76-82.	1.1	1
20	Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets. World Journal of Gastroenterology, 2019, 25, 3136-3150.	1.4	51
21	Evidence-based Surgery of Aortic Regurgitation: Results of a Questionnaire in German-speaking Countries. Thoracic and Cardiovascular Surgeon, 2018, 66, 287-293.	0.4	1
22	Histone deacetylases inhibition: a potential diagnostic and therapeutic target for cancers—reply. Human Pathology, 2018, 71, 167-168.	1.1	0
23	Singleâ€center implementation of endoscopic submucosal dissection (<scp>ESD</scp>) in the colorectum: Low recurrence rate after intentionâ€toâ€treat <scp>ESD</scp> . Digestive Endoscopy, 2018, 30, 354-363.	1.3	19
24	Update on the role and therapeutic potential of polycomb repressive complexes in (biliary tract) cancer. Expert Opinion on Therapeutic Targets, 2018, 22, 1-3.	1.5	4
25	The histone methyltransferase G9a: a new therapeutic target in biliary tract cancer. Human Pathology, 2018, 72, 117-126.	1.1	19
26	Glycine Induces Migration of Microglial BV-2 Cells via SNAT-Mediated Cell Swelling. Cellular Physiology and Biochemistry, 2018, 50, 1460-1473.	1.1	12
27	HDAC-Linked "Proliferative―miRNA Expression Pattern in Pancreatic Neuroendocrine Tumors. International Journal of Molecular Sciences, 2018, 19, 2781.	1.8	20
28	Miniaturization of the Clonogenic Assay Using Confluence Measurement. International Journal of Molecular Sciences, 2018, 19, 724.	1.8	8
29	Endoscopic submucosal dissection (ESD) for anal high-grade intraepithelial neoplasia: a case report. Zeitschrift Fur Gastroenterologie, 2018, 56, 495-498.	0.2	5
30	Comprehensive immunohistochemical analysis of histone deacetylases in pancreatic neuroendocrine tumors: HDAC5 as a predictor of poor clinical outcome. Human Pathology, 2017, 65, 41-52.	1.1	49
31	Thoughts on investigational hedgehog pathway inhibitors for the treatment of cancer. Expert Opinion on Investigational Drugs, 2017, 26, 133-136.	1.9	11
32	The H+/K+ ATPase Inhibitor SCH-28080 Inhibits Insulin Secretion and Induces Cell Death in INS-1E Rat Insulinoma Cells. Cellular Physiology and Biochemistry, 2017, 43, 1037-1051.	1.1	4
33	Thermographic real-time-monitoring of surgical radiofrequency and microwave ablation in a perfused porcine liver model. Oncology Letters, 2017, 15, 2913-2920.	0.8	27
34	SOX9 is a proliferation and stem cell factor in hepatocellular carcinoma and possess widespread prognostic significance in different cancer types. PLoS ONE, 2017, 12, e0187814.	1.1	56
35	IMP2/IGF2BP2 expression, but not IMP1 and IMP3, predicts poor outcome in patients and high tumor growth rate in xenograft models of gallbladder cancer. Oncotarget, 2017, 8, 89736-89745.	0.8	30
36	Biliary tract cancer stem cells - translational options and challenges. World Journal of Gastroenterology, 2017, 23, 2470.	1.4	13

TOBIAS KIESSLICH

#	Article	IF	CITATIONS
37	Deregulated MicroRNAs in Biliary Tract Cancer: Functional Targets and Potential Biomarkers. BioMed Research International, 2016, 2016, 1-15.	0.9	19
38	Current Insights into Long Non-Coding RNAs in Renal Cell Carcinoma. International Journal of Molecular Sciences, 2016, 17, 573.	1.8	66
39	Comprehensive Analysis of miRNome Alterations in Response to Sorafenib Treatment in Colorectal Cancer Cells. International Journal of Molecular Sciences, 2016, 17, 2011.	1.8	32
40	Relevance of MicroRNA200 Family and MicroRNA205 for Epithelial to Mesenchymal Transition and Clinical Outcome in Biliary Tract Cancer Patients. International Journal of Molecular Sciences, 2016, 17, 2053.	1.8	14
41	Back to the start: Evaluation of prognostic markers in gastrointestinal stromal tumors. Molecular and Clinical Oncology, 2016, 4, 763-773.	0.4	7
42	Methylsulfonyl Zn phthalocyanine: A polyvalent and powerful hydrophobic photosensitizer with a wide spectrum of photodynamic applications. Photodiagnosis and Photodynamic Therapy, 2016, 13, 40-47.	1.3	27
43	Reasons for Journal Impact Factor Changes: Influence of Changing Source Items. PLoS ONE, 2016, 11, e0154199.	1.1	35
44	The BMI1 inhibitor PTC-209 is a potential compound to halt cellular growth in biliary tract cancer cells. Oncotarget, 2016, 7, 745-758.	0.8	38
45	Differential role of Hedgehog signaling in human pancreatic (patho-) physiology: An up to date review. World Journal of Gastrointestinal Pathophysiology, 2016, 7, 199.	0.5	18
46	Temoporfin improves efficacy of photodynamic therapy in advanced biliary tract carcinoma: A multicenter prospective phase II study. Hepatology, 2015, 62, 1456-1465.	3.6	56
47	MiRâ€96â€5p influences cellular growth and is associated with poor survival in colorectal cancer patients. Molecular Carcinogenesis, 2015, 54, 1442-1450.	1.3	81
48	The pan-deacetylase inhibitor panobinostat affects angiogenesis in hepatocellular carcinoma models via modulation of CTGF expression. International Journal of Oncology, 2015, 47, 963-970.	1.4	22
49	The green tea catechin epigallocatechin gallate induces cell cycle arrest and shows potential synergism with cisplatin in biliary tract cancer cells. BMC Complementary and Alternative Medicine, 2015, 15, 194.	3.7	57
50	The role of polycomb repressive complexes in biliary tract cancer. Expert Opinion on Therapeutic Targets, 2015, 19, 363-375.	1.5	18
51	Role of histone deacetylases in pancreas: Implications for pathogenesis and therapy. World Journal of Gastrointestinal Oncology, 2015, 7, 473.	0.8	25
52	3-Deazaneplanocin A May Directly Target Putative Cancer Stem Cells in Biliary Tract Cancer. Anticancer Research, 2015, 35, 4697-705.	0.5	19
53	Molecular Targeted Therapies in Hepatocellular Carcinoma: Past, Present and Future. Anticancer Research, 2015, 35, 5737-44.	0.5	61
54	Endoplasmic Reticulum Stress in Pancreatic Neuroendocrine Tumors is Linked to Clinicopathological Parameters and Possible Epigenetic Regulations. Anticancer Research, 2015, 35, 6127-36.	0.5	14

TOBIAS KIESSLICH

#	Article	IF	CITATIONS
55	MicroRNAs Associated with the Efficacy of Photodynamic Therapy in Biliary Tract Cancer Cell Lines. International Journal of Molecular Sciences, 2014, 15, 20134-20157.	1.8	18
56	Robust linear regression model of Ki-67 for mitotic rate in gastrointestinal stromal tumors. Oncology Letters, 2014, 7, 745-749.	0.8	25
57	Real-time analysis of endogenous protoporphyrin IX fluorescence from δ-aminolevulinic acid and its derivatives reveals distinct time- and dose-dependent characteristics <i>in vitro</i> . Journal of Biomedical Optics, 2014, 19, 085007.	1.4	10
58	Photosensitizer Adhered to Cell Culture Microplates Induces Phototoxicity in Carcinoma Cells. BioMed Research International, 2013, 2013, 1-11.	0.9	5
59	A Comprehensive Tutorial onIn VitroCharacterization of New Photosensitizers for Photodynamic Antitumor Therapy and Photodynamic Inactivation of Microorganisms. BioMed Research International, 2013, 2013, 1-17.	0.9	47
60	GERD—Barrett—Adenocarcinoma: Do We Have Suitable Prognostic and Predictive Molecular Markers?. Gastroenterology Research and Practice, 2013, 2013, 1-14.	0.7	11
61	Epigenetic control of epithelial-mesenchymal-transition in human cancer. Molecular and Clinical Oncology, 2013, 1, 3-11.	0.4	100
62	New Applications of Photodynamic Therapy in Biomedicine and Biotechnology. BioMed Research International, 2013, 2013, 1-3.	0.9	20
63	Current Status of Therapeutic Targeting of Developmental Signalling Pathways in Oncology. Current Pharmaceutical Biotechnology, 2012, 13, 2184-2220.	0.9	29
64	Association of stem cell marker expression pattern and survival in human biliary tract cancer. International Journal of Oncology, 2012, 41, 511-522.	1.4	12
65	Influence of Five Potential Anticancer Drugs on Wnt Pathway and Cell Survival in Human Biliary Tract Cancer Cells. International Journal of Biological Sciences, 2012, 8, 15-29.	2.6	25
66	Advances in photodynamic therapy for the treatment of hilar biliary tract cancer. Future Oncology, 2010, 6, 1925-1936.	1.1	12
67	Uptake and phototoxicity of meso-tetrahydroxyphenyl chlorine are highly variable in human biliary tract cancer cell lines and correlate with markers of differentiation and proliferation. Photochemical and Photobiological Sciences, 2010, 9, 734-743.	1.6	31
68	Active Wnt signalling is associated with low differentiation and high proliferation in human biliary tract cancer in vitro and in vivo and is sensitive to pharmacological inhibition. International Journal of Oncology, 2010, 36, 49-58.	3.9	16
69	Photodynamic therapy for non-resectable perihilar cholangiocarcinoma. Photochemical and Photobiological Sciences, 2009, 8, 23-30.	1.6	29